{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T19:06:12Z","timestamp":1790017572882,"version":"4.0.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-024-01324-2","type":"journal-article","created":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T11:06:59Z","timestamp":1726225619000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Latrophilin-3 as a downstream effector of the androgen receptor induces bladder cancer progression"],"prefix":"10.1007","volume":"15","author":[{"given":"Takuro","family":"Goto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Teramoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujiro","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,13]]},"reference":[{"key":"1324_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87\u2013108.","journal-title":"CA Cancer J Clin"},{"key":"1324_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"1324_CR3","unstructured":"SEER Cancer Stat Facts: Bladder Cancer. National Cancer Institute, Bethesda MD.\u00a0 2024.\u00a0http:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html.\u00a0Accessed 8 Jul 2024."},{"key":"1324_CR4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1080\/14737140.2020.1744437","volume":"20","author":"T Goto","year":"2020","unstructured":"Goto T, Miyamoto H. Why has the prognosis for muscle-invasive bladder cancer not significantly improved after decades of therapeutic advancements? Expert Opin Anticancer Ther. 2020;20:229\u201331.","journal-title":"Expert Opin Anticancer Ther"},{"key":"1324_CR5","doi-asserted-by":"publisher","first-page":"566","DOI":"10.3390\/cancers15030566","volume":"15","author":"J Esteban-Villarrubia","year":"2023","unstructured":"Esteban-Villarrubia J, Torres-Jim\u00e9nez J, Bueno-Bravo C, Garcia-Mondaray R, Subiela JD, Gajate P. Current and future landscape of perioperative treatment for muscle-invasive bladder cancer. Cancers. 2023;15:566.","journal-title":"Cancers"},{"key":"1324_CR6","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1093\/jnci\/djk113","volume":"99","author":"H Miyamoto","year":"2007","unstructured":"Miyamoto H, Yang Z, Chen YT, et al. Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst. 2007;99:558\u201368.","journal-title":"J Natl Cancer Inst"},{"key":"1324_CR7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.mce.2017.06.021","volume":"465","author":"S Inoue","year":"2018","unstructured":"Inoue S, Mizushima T, Miyamoto H. Role of the androgen receptor in urothelial cancer. Mol Cell Endocrinol. 2018;465:73\u201381.","journal-title":"Mol Cell Endocrinol"},{"key":"1324_CR8","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.3390\/cells10051169","volume":"10","author":"H Ide","year":"2021","unstructured":"Ide H, Miyamoto H. Steroid hormone receptor signaling in bladder cancer: a potential target for enhancing the efficacy of conventional non-surgical therapy. Cells. 2021;10:1169.","journal-title":"Cells"},{"key":"1324_CR9","doi-asserted-by":"publisher","first-page":"e43215","DOI":"10.1016\/j.urolonc.2016.05.016","volume":"34","author":"T Kawahara","year":"2016","unstructured":"Kawahara T, Ide H, Kashiwagi E, et al. Enzalutamide inhibits androgen receptor-positive bladder cancer cell growth. Urol Oncol. 2016;34:e43215\u201323.","journal-title":"Urol Oncol"},{"key":"1324_CR10","doi-asserted-by":"publisher","first-page":"23239","DOI":"10.1074\/jbc.271.38.23239","volume":"271","author":"BA Davletov","year":"1996","unstructured":"Davletov BA, Shamotienko OG, Lelianova VG, Grishin EV, Ushkaryov YA. Isolation and biochemical characterization of a Ca2+-independent \u03b1-latrotoxin-binding protein. J Biol Chem. 1996;271:23239\u201345.","journal-title":"J Biol Chem"},{"key":"1324_CR11","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1006\/bbrc.1996.1598","volume":"227","author":"VG Krasnoperov","year":"1996","unstructured":"Krasnoperov VG, Beavis R, Chepurny OG, Little AR, Plotnikov AN, Petrenko AG. The calcium-independent receptor of \u03b1-latrotoxin is not a neurexin. Biochem Biophys Res Commun. 1996;227:868\u201375.","journal-title":"Biochem Biophys Res Commun"},{"key":"1324_CR12","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1515\/bmc-2014-0032","volume":"5","author":"DG Meza-Aguilar","year":"2014","unstructured":"Meza-Aguilar DG, Boucard AA. Latrophilins updated. Biomol Concepts. 2014;5:457\u20138.","journal-title":"Biomol Concepts"},{"key":"1324_CR13","doi-asserted-by":"publisher","first-page":"32715","DOI":"10.1074\/jbc.273.49.32715","volume":"273","author":"S Sugita","year":"1998","unstructured":"Sugita S, Ichtchenko K, Khvotchev M, S\u00fcdhof TC. \u03b1-Latrotoxin receptor CIRL\/latrophilin 1 (CL1) defined an unusual family of ubiquitous G-protein-linked receptors: G-protein coupling not required for triggering exocytosis. J Biol Chem. 1998;273:32715\u201324.","journal-title":"J Biol Chem"},{"key":"1324_CR14","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1074\/jbc.M113.504779","volume":"289","author":"AA Boucard","year":"2014","unstructured":"Boucard AA, Maxeiner S, S\u00fcdhol TC. Latrophilins function as heterophilic cell-adhesion molecules by binding to teneurins. J Biol Chem. 2014;289:387\u2013402.","journal-title":"J Biol Chem"},{"key":"1324_CR15","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.neubiorev.2021.11.041","volume":"132","author":"SL Regan","year":"2022","unstructured":"Regan SL, Williams MT, Vorhees CV. Review of rodent models of attention deficit hyperactivity disorder. Neurosci Biobehav Rev. 2022;132:621\u201337.","journal-title":"Neurosci Biobehav Rev"},{"key":"1324_CR16","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.biopsych.2012.05.027","volume":"72","author":"MV Lombardo","year":"2012","unstructured":"Lombardo MV, Ashwin E, Auyeung B, et al. Fetal programming effects of testosterone on the reward system and behavioral approach tendencies in humans. Biol Psychiatry. 2012;72:839\u201347.","journal-title":"Biol Psychiatry"},{"key":"1324_CR17","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.biopsych.2016.09.022","volume":"82","author":"K Kosidou","year":"2017","unstructured":"Kosidou K, Dalman C, Widman L, et al. Maternal polycystic ovary syndrome and risk for attention-deficit\/hyperactivity disorder in the offspring. Biol Psychiatry. 2017;82:651\u20139.","journal-title":"Biol Psychiatry"},{"key":"1324_CR18","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1530\/ERC-11-0010","volume":"18","author":"Y Zheng","year":"2011","unstructured":"Zheng Y, Izumi K, Yao JL, Miyamoto H. Dihydritestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells. Endocr Relat Cancer. 2011;18:451\u201364.","journal-title":"Endocr Relat Cancer"},{"key":"1324_CR19","first-page":"461","volume":"4","author":"Y Li","year":"2014","unstructured":"Li Y, Ishiguro H, Kawahara T, Miyamoto Y, Izumi K, Miyamoto H. GATA3 in the urinary bladder: suppression of neoplastic transformation and down-regulation by androgens. Am J Cancer Res. 2014;4:461\u201373.","journal-title":"Am J Cancer Res"},{"key":"1324_CR20","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1158\/1535-7163.MCT-20-0050","volume":"19","author":"T Mizushima","year":"2020","unstructured":"Mizushima T, Jiang G, Kawahara T, et al. Androgen receptor signaling reduces the efficacy of bacillus Calmette-Gu\u00e9rin therapy for bladder cancer via modulating Rab27-induced exocytosis. Mol Cancer Ther. 2020;19:1930\u201342.","journal-title":"Mol Cancer Ther"},{"key":"1324_CR21","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/mc.21833","volume":"52","author":"K Izumi","year":"2013","unstructured":"Izumi K, Zheng Y, Hsu JW, Chang C, Miyamoto H. Androgen receptor signals regulate UDP-glucuronosyltransferases in the urinary bladder: a potential mechanism of androgen-induced bladder carcinogenesis. Mol Carcinogen. 2013;52:94\u2013102.","journal-title":"Mol Carcinogen"},{"key":"1324_CR22","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1002\/mc.23783","volume":"63","author":"T Goto","year":"2024","unstructured":"Goto T, Yasui M, Teramoto Y, Nagata Y, Mizushima T, Miyamoto H. Latrophilin-3 as a downstream effector of the androgen receptor induces urothelial tumorigenesis. Mol Carcinog. 2024;63:1847\u201354.","journal-title":"Mol Carcinog"},{"key":"1324_CR23","doi-asserted-by":"publisher","first-page":"7289","DOI":"10.3390\/ijms25137289","volume":"25","author":"Y Teramoto","year":"2024","unstructured":"Teramoto Y, Elahi Najafi MA, Matsukawa T, Sharma A, Goto T, Miyamoto H. Latrophilins as downstream effectors of androgen receptors including a splice variant, AR-V7, induce prostate cancer progression. Int J Mol Sci. 2024;25:7289.","journal-title":"Int J Mol Sci"},{"key":"1324_CR24","doi-asserted-by":"publisher","first-page":"13733","DOI":"10.3390\/ijms241813733","volume":"24","author":"MA Elahi Najafi","year":"2023","unstructured":"Elahi Najafi MA, Yasui M, Teramoto Y, Tatenuma T, Jiang G, Miyamoto H. GABBR2 as a downstream effector of the androgen receptor induces cisplatin resistance in bladder cancer. Int J Mol Sci. 2023;24:13733.","journal-title":"Int J Mol Sci"},{"key":"1324_CR25","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1111\/j.1464-410X.2011.10706.x","volume":"109","author":"H Miyamoto","year":"2012","unstructured":"Miyamoto H, Yao JL, Chaux A, et al. Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder. BJU Int. 2012;109:1716\u201326.","journal-title":"BJU Int"},{"key":"1324_CR26","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl. 2013;48:452\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"1324_CR27","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/nrc2069","volume":"7","author":"RT Dorsam","year":"2007","unstructured":"Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat Rev Cancer. 2007;7:79\u201394.","journal-title":"Nat Rev Cancer"},{"key":"1324_CR28","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/nchembio.642","volume":"7","author":"K Qin","year":"2011","unstructured":"Qin K, Dong C, Wu G, Lambert NA. Inactive-state preassembly of Gq-coupled receptors and Gq heterodimers. Nat Chem Biol. 2011;7:740\u20137.","journal-title":"Nat Chem Biol"},{"key":"1324_CR29","doi-asserted-by":"publisher","first-page":"676","DOI":"10.4143\/crt.2015.153","volume":"48","author":"MS Jeon","year":"2016","unstructured":"Jeon MS, Song SH, Yun J, et al. Aberrant epigenetic modification of LPHN2 function as a potential cisplatin-specific biomarker for human gastrointestinal cancer. Cancer Res Treat. 2016;48:676\u201386.","journal-title":"Cancer Res Treat"},{"key":"1324_CR30","doi-asserted-by":"publisher","first-page":"353","DOI":"10.4149\/gpb_2018008","volume":"37","author":"Z Kocibalova","year":"2018","unstructured":"Kocibalova Z, Guzyova M, Imrichova D, Sulova Z, Breier A. Overexpression of the ABCB1 drug transporter in acute myeloid leukemia cells is associated with downregulation of latrophilin-1. Gen Physiol Biophys. 2018;37:353\u20137.","journal-title":"Gen Physiol Biophys"},{"key":"1324_CR31","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.3389\/fimmu.2019.01594","volume":"10","author":"IM Yasinska","year":"2019","unstructured":"Yasinska IM, Sakhnevych SS, Pavlova L, et al. The Tim-3-galectin-9 pathway and its regulatory mechanisms in human breast cancer. Front Immunol. 2019;10:1594.","journal-title":"Front Immunol"},{"key":"1324_CR32","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/s41374-021-00721-3","volume":"102","author":"J Wang","year":"2022","unstructured":"Wang J, Xi S, Zhao Q, et al. Driver mutations in ADGRL3 are involved in the evolution of ependymoma. Lab Invest. 2022;102:702\u201310.","journal-title":"Lab Invest"},{"key":"1324_CR33","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.neuron.2012.01.018","volume":"73","author":"ML O\u2019Sullivan","year":"2012","unstructured":"O\u2019Sullivan ML, de Wit J, Savas JN, et al. Postsynaptic FLRT proteins are endogenous ligands for the black widow spider venom receptor latrophilin and regulate excitatory synapse development. Neuron. 2012;73:903\u201310.","journal-title":"Neuron"},{"key":"1324_CR34","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/nature09208","volume":"466","author":"Z Kan","year":"2010","unstructured":"Kan Z, Jaiswal BS, Stinson J, et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature. 2010;466:869\u201373.","journal-title":"Nature"},{"key":"1324_CR35","doi-asserted-by":"publisher","first-page":"49169","DOI":"10.18632\/oncotarget.9994","volume":"7","author":"E Kashiwagi","year":"2016","unstructured":"Kashiwagi E, Ide H, Inoue S, et al. Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer. Oncotarget. 2016;7:49169\u201379.","journal-title":"Oncotarget"},{"key":"1324_CR36","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1111\/cas.14557","volume":"111","author":"H Ide","year":"2020","unstructured":"Ide H, Goto T, Teramoto Y, et al. FOXO1 inactivation induces cisplatin resistance in bladder cancer. Cancer Sci. 2020;111:3397\u2013400.","journal-title":"Cancer Sci"},{"key":"1324_CR37","doi-asserted-by":"publisher","first-page":"10030","DOI":"10.3390\/ijms221810030","volume":"22","author":"Y Teramoto","year":"2021","unstructured":"Teramoto Y, Jiang G, Goto T, et al. Androgen receptor signaling induces cisplatin resistance via down-regulating GULP1 expression in bladder cancer. Int J Mol Sci. 2021;22:10030.","journal-title":"Int J Mol Sci"},{"key":"1324_CR38","doi-asserted-by":"publisher","first-page":"643870","DOI":"10.3389\/fendo.2021.643870","volume":"12","author":"T Goto","year":"2021","unstructured":"Goto T, Miyamoto H. The role of estrogen receptors in urothelial cancer. Front Endocrinol. 2021;12:643870.","journal-title":"Front Endocrinol"},{"key":"1324_CR39","doi-asserted-by":"publisher","first-page":"6596","DOI":"10.21037\/tcr.2020.01.06","volume":"9","author":"Y Nagata","year":"2020","unstructured":"Nagata Y, Miyamoto H. The prognostic role of steroid hormone receptor signaling pathways in urothelial carcinoma. Transl Cancer Res. 2020;9:6596\u2013608.","journal-title":"Transl Cancer Res"},{"key":"1324_CR40","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1530\/ERC-20-0004","volume":"27","author":"H Ide","year":"2020","unstructured":"Ide H, Mizushima T, Jiang G, et al. FOXO1 as a tumor suppressor inactivated via AR\/ER\u03b2 signals in urothelial cells. Endocr Relat Cancer. 2020;27:231\u201344.","journal-title":"Endocr Relat Cancer"},{"key":"1324_CR41","doi-asserted-by":"crossref","unstructured":"Tatenuma T, Matsukawa T, Goto T, et al. GULP1 as a downstream effector of the estrogen receptor-\u03b2 modulates cisplatin sensitivity in bladder cancer. Cancer Genom Proteom. 2024 (in press).","DOI":"10.1097\/01.JU.0001008756.24343.22.14"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-024-01324-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-024-01324-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-024-01324-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T11:39:25Z","timestamp":1726227565000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-024-01324-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,13]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1324"],"URL":"https:\/\/doi.org\/10.1007\/s12672-024-01324-2","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,13]]},"assertion":[{"value":"17 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Appropriate approval from the Institutional Review Boards at the University of Rochester Medical Center and The Johns Hopkins Hospital, including the request to waive the documentation of informed consent from the patients, was obtained before construction and use of the set of bladder TMA.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and informed consent"}}],"article-number":"440"}}